Current aspects in the pathogenesis, diagnosis, and therapy of myasthenia gravis;Aktuelle aspekte in der pathogenese, diagnostik und therapie der myasthenia gravis

Aktuelle Neurologie

Volumn 32, Issue 1, 2005, Pages 3-9

  Jander, Sebastian ^a,b   Hartung, H P ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; AUTOANTIBODY; AZATHIOPRINE; CALCIUM ANTAGONIST; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOSKELETON PROTEIN; GAMMA INTERFERON; GUANOSINE DERIVATIVE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE; RITUXIMAB; RYANODINE RECEPTOR; TRIMETHOPRIM; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ALOPECIA; ANEMIA; ANTIGEN SPECIFICITY; ARTHRALGIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CARCINOGENESIS; CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL TRIAL; CUSHING SYNDROME; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEMORRHAGIC CYSTITIS; HEPATITIS; HIRSUTISM; HUMAN; HYPOKALEMIA; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INFERTILITY; KIDNEY FAILURE; LEUKOPENIA; LUNG FIBROSIS; MACROCYTIC ANEMIA; MOOD DISORDER; MUSCLE HYPERTONIA; MYASTHENIA GRAVIS; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PLASMAPHERESIS; PNEUMONIA; POLYNEUROPATHY; PROGNOSIS; PROTEIN DEGRADATION; PSYCHOSIS; REVIEW; THYMECTOMY; TREMOR;

EID: 14344264862     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-834610     Document Type: Review

References (95)

1. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797-1810
2. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2: 797-804
3. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61: 1652-1661
4. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004; 29: 484-505
5. Lindstrom JM, Seybold ME, Lennon VA et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054-1059
6. Toyka KV, Drachman DB, Griffin DE et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 1977; 296: 125-131
7. Toyka KV, Heininger K. Acetylcholine receptor antibodies in the diagnosis of myasthenia gravis. Study of 406 confirmed cases. Dtsch Med Wochenschr 1986; 111: 1435-1439
8. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003; 2: 99-106
9. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986; 1: 116-119
10. Mier AK, Havard CW. Diaphragmatic myasthenia in mother and child. Postgrad Med J 1985; 61: 725-727
11. Heckmatt JZ, Placzek M, Thompson AH et al. An unusual case of neonatal myasthenia. J Child Neurol 1987; 2: 63-66
12. Burges J, Vincent A, Molenaar PC et al. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994; 17: 1393-1400
13. Hoch W, McConville J, Helms S et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-368
14. Evoli A, Tonali PA, Padua L et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126: 2304-2311
15. McConville J, Farrugia ME, Beeson D et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55: 580-584
16. Zhou L, McConville J, Chaudhry V et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004; 30: 55-60
17. Sanders DB, El Salem K, Massey JM et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60: 1978-1980
18. Scuderi F, Marino M, Colonna L et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002; 82: 1139-1146
19. Abicht A, Lochmüller H. What's in the serum of seronegative MG and LEMS? MuSK et al. Neurology 2002; 59: 1672-1673
20. Sahashi K, Engel AG, Lambert EH, Howard Jr FM. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980; 39: 160-172
21. Vincent A, McConville J, Farrugia ME et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003; 998: 324-335
22. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002; 25: 4-16
23. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004; 62: 1945-1950
24. Lindstrom J. Is "seronegative" MG explained by autoantibodies to MuSK? Neurology 2004; 62: 1920-1921
25. Agius MA, Zhu S, Kirvan CA et al. Rapsyn antibodies in myasthenia gravis. Ann N Y Acad Sci 1998; 841: 516-521
26. Baets M De, Stassen M, Losen M et al. Immunoregulation in experimental autoimmune myasthenia gravis - about T cells, antibodies, and endplates. Ann N Y Acad Sci 2003; 998: 308-317
27. Aarli JA, Stefansson K, Marion LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990; 82: 284-288
28. Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000; 247: 369-375
29. Voltz RD, Albrich WC, Nagele A et al. Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 1997; 49: 1454-1457
30. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 2001; 57: 1579-1582
31. Yamamoto AM, Gajdos P, Eymard B et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001; 58: 885-890
32. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980; 103: 579-601
33. Agius MA, Richman DP, Fairclough RH et al. Three forms of immune myasthenia. Ann N Y Acad Sci 2003; 998: 453-456
34. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-15
35. Romi F, Gilhus NE, Varhaug JE et al. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol 2002; 9: 55-61
36. Graves M, Katz JS. Myasthenia gravis. Curr Treat Options Neurol 2004; 6: 163-171
37. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998; 50: 1778-1783
38. Hohlfeld R, Toyka KV, Besinger UA et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985; 17: 238-242
39. Michels M, Hohlfeld R, Hartung HP et al. Myasthenia gravis: discontinuation of long-term azathioprine. Ann Neurol 1988; 24: 798
40. Tindall RS, Rollins JA, Phillips JT et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316: 719-724
41. Behrend M, Lueck R, Pichlmayr R. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection. Transplant Proc 1997; 29: 2927-2929
42. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993; 696: 63-87
43. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998; 51: 912-913
44. Chaudhry V, Cornblath DR, Griffin JW et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2000; 56: 94-96
45. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2000; 56: 97-99
46. Meriggioli MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000; 23: 1287-1289
47. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001; 185: 119-122
48. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001; 46: 79-82
49. Meriggioli MN, Ciafaloni E, Al Hayk KA et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61: 1438-1440
50. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003; 998: 494-499
51. Feo LG de, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002; 26: 31-36
52. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "Rebooting" with high-dose cyclophosphamide. Ann Neurol 2003; 53: 29-34
53. Gladstone DE, Brannagan III TH, Schwartzman RJ et al. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry 2004; 75: 789-791
54. Zaja F, Russo D, Fuga G et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55: 1062-1063
55. Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003; 143: 674-677
56. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004; 77: 196-197
57. Gajdos P, Chevret S, Clair B et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41: 789-796
58. Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 2000; 23: 551-555
59. Wolfe GI, Barohn RJ, Foster BM et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002; 26: 549-552
60. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev, 2002 CD002275
61. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis (Cochrane Review). Cochrane Database Syst Rev, 2003 CD002277
62. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004; 291: 2367-2375
63. Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000; 247: 510-513
64. Flachenecker P, Taleghani BM, Gold R et al. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide. Transfus Sci 1998; 19, Suppl: 43-46
65. Psaridi-Linardaki L, Mamalaki A, Tzartos SJ. Future therapeutic strategies in autoimmune myasthenia gravis. Ann N Y Acad Sci 2003; 998: 539-548
66. McQuillen MP, Leone MG. A treatment carol: thymectomy revisited. Neurology 1977; 27: 1103-1106
67. Buckingham JM, Howard Jr FM, Bernatz PE et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg 1976; 184: 453-458
68. Yim AP, Kay RL, Ho JK. Video-assisted thoracoscopic thymectomy for myasthenia gravis. Chest 1995; 108: 1440-1443
69. Ruckert JC, Gellert K, Muller JM. Operative technique for thoracoscopic thymectomy. Surg Endosc 1999; 13: 943-946
70. Wright GM, Barnett S, Clarke CP. Video-assisted thoracoscopic thymectomy for myasthenia gravis. Intern Med J 2002; 32: 367-371
71. Mantegazza R, Baggi F, Bernasconi P et al. Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. J Neurol Sci 2003; 212: 31-36
72. Ruckert JC, Sobel HK, Gohring S et al. Matched-pair comparison of three different approaches for thymectomy in myasthenia gravis. Surg Endosc 2003; 17: 711-715
73. Zielinski M, Kuzdzal J, Szlubowski A, Soja J. Transcervical-subxiphoid- videothoracoscopic "maximal" thymectomy - operative technique and early results. Ann Thorac Surg 2004; 78: 404-409
74. Zielinski M, Kuzdzal J, Szlubowski A, Soja J. Comparison of late results of basic transsternal and extended transsternal thymectomies in the treatment of myasthenia gravis. Ann Thorac Surg 2004; 78: 253-258
75. Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 1990; 40: 1828-1829
76. Wolfe GI, Kaminski HJ, Jaretzki III A et al. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci 2003; 998: 473-480
77. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793
78. Balasa B, Sarvetnick N. Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis. Immunol Today 2000; 21: 19-23
79. Link H, Olsson O, Sun J et al. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest 1991; 87: 2191-2195
80. Balasa B, Deng C, Lee J et al. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 1997; 186: 385-391
81. Balasa B, Deng C, Lee J et al. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J Immunol 1998; 161: 2856-2862
82. Moiola L, Galbiati F, Martino G et al. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol 1998; 28: 2487-2497
83. Shi FD, Wang HB, Li H et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000; 1: 245-251
84. Im SH, Barchan D, Maiti PK et al. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J 2001; 15: 2140-2148
85. Jander S, Stoll G. Increased serum levels of the interferon-gamma- inducing cytokine interleukin-18 in myasthenia gravis. Neurology 2002; 59: 287-289
86. Pachner AR. Antigen-specific immunotherapy in myasthenia gravis: failed promise and new hope. J Neuroimmunol 2004; 152: vii-viii
87. Sela M, Mozes E. Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci U S A 2004; 101, Suppl 2: 14586-14592
88. Katz-Levy Y, Kirshner SL, Sela M, Mozes E. Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Proc Natl Acad Sci U S A 1993; 90: 7000-7004
89. Nicolle MW, Nag B, Sharma SD et al. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994; 93: 1361-1369
90. Im SH, Barchan D, Fuchs S, Souroujon MC. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest 1999; 104: 1723-1730
91. Paas-Rozner M, Dayan M, Paas Y et al. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc Natl Acad Sci U S A 2000; 97: 2168-2173
92. Souroujon MC, Maiti PK, Feferman T et al. Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors. Ann N Y Acad Sci 2003; 998: 533-536
93. Drachman DB, Wu JM, Miagkov A et al. Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the "guided missile" strategy. Ann N Y Acad Sci 2003; 998: 520-532
94. Paas-Rozner M, Sela M, Mozes E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci U S A 2001; 98: 12642-12647
95. Dayan M, Sthoeger Z, Neiman A et al. Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis. Hum Immunol 2004; 65: 571-577